A case-control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe

Revista Portuguesa de Cardiologia

Volumn 29, Issue 10, 2010, Pages 1481-1493

  Ferreira, Luís ^a   Belo, Adriana ^a   Abreu Lima, Cassiano ^a  

^a NONE

Author keywords

Cardiovascular risk; Cardiovascular risk factors; Schizophrenia; SCORE charts

Indexed keywords

BENZODIAZEPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL OBESITY; ADULT; ALCOHOL ABUSE; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PORTUGAL; PRESCRIPTION; PREVALENCE; PRIMARY MEDICAL CARE; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; SMOKING; WEIGHT GAIN;

ADULT; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; PORTUGAL; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA;

EID: 78751686105     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998; 173:11-53.
2. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212-217.
3. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Hearth J. 2005; 150:1115-1121. (Pubitemid 41773510)
4. Bernardo M, Cañas F, Banegas JR, Casademont J, Riesgo Y, Varela C on behalf of the RICAVA Study Group. Prevalence and awareness of cardiovascular risk factors in patients with schizophrenia: a cross-sectional study in a low cardiovascular disease risk geographical area. Eur Psychiatry 2009; 24: 431-41
5. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005; 80:45-53.
6. Sowden GL, Huffman JC. The impact of mental illness on cardiac outcomes: a review for the cardiologist. Int J Cardiol 2009;132:30-37.
7. Oud MJT, Meyboom-de Jong B. Somatic diseases in patients with schizophrenia in general practice: their prevalence and health care. BMC Fam Pract 2009;10:32.
8. Graham I, Atar D, Borch-Johnsen K, et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28:2375-2414.
9. Fiuza M, Cortez-Dias N, Martins S, Belo A on behalf of the VALSIM Study investigators. Metabolic syndrome in Portugal. Prevalence and implications for cardiovascular risk. Results from the VALSIM Study. Rev Port Cardiol 2008; 27:1495-1529.
10. NCEP ATP III http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf
11. SPSS Inc. an IBM Company. Chicago, Illinois.
12. Mancia G, De Backer G, Dominiczak A, et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007; 28:1462-1536.
13. De Hert M, Dekker JM, Wood D, Kahal KG, Holt RIG, Möller, H-J. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Euro Psychiatry 2009;24:412-424.
14. Nashrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizoph Res. 2006; 86:15-22.
15. Charney DS, Mihic SJ, Harris AH. Hypnotics and sedatives. In: Brunton LL, Lazo JS and Parker KL (editors): Goodman & Gilman's The Pharmacologic Basis of Therapeutics. New York: McGraw-Hill Medical Publishing Division; 2006. p. 407.
16. Arango C, Bobes J, Aranda P, Carmena R, Garcia-Garcia M, Rejas J on behalf of the CLAMORS Study Collaborative Group. A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study. Schizophr Res 2008; 104:1-12.
17. Gual A, Contel M, Segura L, Ribas A, Colom J. The ISCA (Systematic Interview of Alcohol Consumption), a new instrument to detect risky drinking. Med Clin (Barc) 2001; 117:685-689.